Role of Mediterranean diet in preventing platinum based gastrointestinal toxicity in gynecolocological malignancies: A single Institution experience

Table 1 Clinical and nutritional characteristics of the sample at baseline

Characteristics	n = 22
Age (yr, mean value)	61
Weight (kg, mean value ± SD)	64 ± 14.2
BMI (mean value ± SD)	25 ± 5.2
Allergies, n (%)
Yes	15 (68.2)
No	7 (31.8)
Smoke, n (%)
Yes	5 (22.7)
No	17 (77.3)
Alcohol, n (%)
Yes	8 (36.4)
No	14 (63.6)
Type of gynecological cancer, n (%)
Cervical cancer	5 (22.7)
Endometrial cancer	2 (9.1)
Ovarian cancer	15 (68.2)
Chemotherapy treatment, n (%)
Carboplatin	2 (9.2)
Carboplatin - Bevacizumab	1 (4.5)
Carboplatin - Caelyx	3 (13.6)
Carboplatin - Gemcitabine	2 (9.2)
Carboplatin - Taxol	9 (40.9)
Carboplatin - Gemcitabine - Bevacizumab	1 (4.5)
Cisplatin	3 (13.6)
Cisplatin – Bevacizumab	1 (4.5)
Number of lines, n (%)
I	14 (63.6)
II	7 (31.8)
III	1 (4.6)
Nutritional requirements
BEE in kcal (Average value ± SD)	1262.5 ± 146.6
TEE in kcal (Average value ± SD)	1678.9 ± 177.1
Mediterranean diet adherence
MDSS (mean value ± SD)	12.5 ± 3.4
MDSS ≥ 13, n (%)	12 (54.5)
MDSS < 13	10 (45.5)

SD: Standard deviation; MDSS: Mediterranean diet serving score; BMI: Body mass index; TEE: Total energy expenditure; BEE: Basal energy expenditure.